Cargando…

Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels

There are many determinants of vancomycin clearance, but these have not been analyzed separately in populations with different levels of renal function, which could be why some important factors have been missed. The aim of our study was to compare the pharmacokinetic parameters and factors that may...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaric, Radica Zivkovic, Milovanovic, Jasmina, Rosic, Nikola, Milovanovic, Dragan, Zecevic, Dejana Ruzic, Folic, Marko, Jankovic, Slobodan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6227840/
https://www.ncbi.nlm.nih.gov/pubmed/30426090
http://dx.doi.org/10.1515/med-2018-0068
_version_ 1783370002527682560
author Zaric, Radica Zivkovic
Milovanovic, Jasmina
Rosic, Nikola
Milovanovic, Dragan
Zecevic, Dejana Ruzic
Folic, Marko
Jankovic, Slobodan
author_facet Zaric, Radica Zivkovic
Milovanovic, Jasmina
Rosic, Nikola
Milovanovic, Dragan
Zecevic, Dejana Ruzic
Folic, Marko
Jankovic, Slobodan
author_sort Zaric, Radica Zivkovic
collection PubMed
description There are many determinants of vancomycin clearance, but these have not been analyzed separately in populations with different levels of renal function, which could be why some important factors have been missed. The aim of our study was to compare the pharmacokinetic parameters and factors that may affect vancomycin pharmacokinetics in groups of patients with normal renal function and in those with chronic kidney failure. The study used a population pharmacokinetic modeling approach, based on plasma vancomycin concentrations and other data from 78 patients with chronic kidney failure and 32 patients with normal renal function. The model was developed using NONMEM software and validated by bootstrapping. The final model for patients with impaired kidney function was described by the following equation: CL (L/h) = 0.284 + 0.000596 x DD + 0.00194 x AST, and that for the patients with normal kidney function by: CL (L/h) = 0.0727 + 0.205 x FIB. If our results are confirmed by new studies on two similar populations, these factors could be considered when dosing vancomycin in patients with chronically damaged kidneys, as well as in patients with normal kidneys who frequently require high doses of vancomycin.
format Online
Article
Text
id pubmed-6227840
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-62278402018-11-13 Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels Zaric, Radica Zivkovic Milovanovic, Jasmina Rosic, Nikola Milovanovic, Dragan Zecevic, Dejana Ruzic Folic, Marko Jankovic, Slobodan Open Med (Wars) Regular Articles There are many determinants of vancomycin clearance, but these have not been analyzed separately in populations with different levels of renal function, which could be why some important factors have been missed. The aim of our study was to compare the pharmacokinetic parameters and factors that may affect vancomycin pharmacokinetics in groups of patients with normal renal function and in those with chronic kidney failure. The study used a population pharmacokinetic modeling approach, based on plasma vancomycin concentrations and other data from 78 patients with chronic kidney failure and 32 patients with normal renal function. The model was developed using NONMEM software and validated by bootstrapping. The final model for patients with impaired kidney function was described by the following equation: CL (L/h) = 0.284 + 0.000596 x DD + 0.00194 x AST, and that for the patients with normal kidney function by: CL (L/h) = 0.0727 + 0.205 x FIB. If our results are confirmed by new studies on two similar populations, these factors could be considered when dosing vancomycin in patients with chronically damaged kidneys, as well as in patients with normal kidneys who frequently require high doses of vancomycin. De Gruyter 2018-10-22 /pmc/articles/PMC6227840/ /pubmed/30426090 http://dx.doi.org/10.1515/med-2018-0068 Text en © 2018 Radica Zivkovic Zaric et al., published by De Gruyter http://creativecommons.org/licenses/by-nc-nd/4.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
spellingShingle Regular Articles
Zaric, Radica Zivkovic
Milovanovic, Jasmina
Rosic, Nikola
Milovanovic, Dragan
Zecevic, Dejana Ruzic
Folic, Marko
Jankovic, Slobodan
Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels
title Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels
title_full Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels
title_fullStr Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels
title_full_unstemmed Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels
title_short Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels
title_sort pharmacokinetics of vancomycin in patients with different renal function levels
topic Regular Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6227840/
https://www.ncbi.nlm.nih.gov/pubmed/30426090
http://dx.doi.org/10.1515/med-2018-0068
work_keys_str_mv AT zaricradicazivkovic pharmacokineticsofvancomycininpatientswithdifferentrenalfunctionlevels
AT milovanovicjasmina pharmacokineticsofvancomycininpatientswithdifferentrenalfunctionlevels
AT rosicnikola pharmacokineticsofvancomycininpatientswithdifferentrenalfunctionlevels
AT milovanovicdragan pharmacokineticsofvancomycininpatientswithdifferentrenalfunctionlevels
AT zecevicdejanaruzic pharmacokineticsofvancomycininpatientswithdifferentrenalfunctionlevels
AT folicmarko pharmacokineticsofvancomycininpatientswithdifferentrenalfunctionlevels
AT jankovicslobodan pharmacokineticsofvancomycininpatientswithdifferentrenalfunctionlevels